Antigen-restricted Candida albicans Th17 cells link oral-gut immunity and adopt pathogenic features during intestinal inflammation

Read full text
Authors: Gabriela Rios Martini, Philipp Hofmann, Ann-Kristin Kamps, Amos Weichberger, Ekaterina Tikhonova, Aidan Conroy, Xiangyu Pan, Diana Milagros Namuch, Laura Rathjens, Arne Bergfeld, Susanna Nikolaus, Jeanette Riffert
+18 more Florian Tran, Konrad Aden, Maria Witte, Clemens Schafmayer, Dora Stölzl, Stephan Weidinger, Markus M. Heimesaat, Miriam Cyris, Ann-Kristin Härdter, Christof Dörfer, Robert Żarnowski, David R. Andes, Sascha Brunke, Bernhard Hube, Alexander Scheffold, Iliyan D. Iliev, Stefan Schreiber, Petra Bacher
Cited by: 1
References: 92

Abstract

The commensal yeast Candida albicans is a major inducer of human mucosal Th17 cells. How C. albicans drives Th17 cell responses at homeostasis, and whether such responses contribute to inflammatory diseases, remains poorly understood. Here, we showed that C. albicans-reactive Th17 cells targeted a limited set of proteins enriched in fungal extracellular vesicles. At homeostasis, these cells predominantly resided in the oral mucosa. However, T cell receptor profiling revealed shared clonotypes across oral and gut tissues, with C. albicans being a major driver of this repertoire overlap. In patients with Crohn's disease, C. albicans-specific Th17 cells with features of oral priming were enriched in intestinal tissues, where they retained their focused antigen specificity but acquired pathogenic Th17 cell traits. Together, our results reveal a stable, antigen-restricted C. albicans Th17 subset that is shared across mucosal sites and undergoes functional adaptation in the inflamed intestine. These cells represent a potential target for immune modulation in Crohn's disease.

Fields of Study & Subjects

Antifungal resistance and susceptibility Inflammatory Bowel Disease Psoriasis: Treatment and Pathogenesis

Publication details

Journal / source
Immunity
Publisher
Elsevier BV
Volume
59
Issue
9
Pages
2545–2561.e10
Publication date
14 July 2026
Language
EN